Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)
- 519 Downloads
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [PCV13] is approved for protection against pneumococcal disease in children aged 6 weeks to 5 years and adults aged ≥50 years.
In randomized trials in adults aged 60–64 years (not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [PPV23]) and ≥70 years (previously vaccinated with PPV23), PCV13 was non-inferior to PPV23 in opsonophagocytic assay (OPA) geometric mean titres (GMTs) for all 12 serotypes common to the two vaccines. More PCV13 than PPV23 recipients had ≥4-fold increases in serotype 6A OPA GMTs (serotype 6A is not included in PPV23). PCV13 recipients also had higher OPA GMTs and met superiority criteria for most serotypes.
Adults aged 50–59 years had antibody responses to PCV13 that were noninferior to those in adults aged 60–64 years for all included serotypes. PCV13 administered concomitantly with trivalent inactivated influenza vaccine in adults aged 50–59 or ≥65 years produced antibody responses that were noninferior to those following sequential administration, except for influenza strain A/H3N2 and pneumococcal serotype 19F in those aged ≥65 years. Antibody responses were numerically higher with sequential administration, although the clinical significance of this is unknown.
Adverse events within 14 days of vaccination were mostly of mild-to-moderate severity, with serious events occurring in 0.2–1.4% of PCV13 and 0.4–1.7% of PPV23 recipients.
KeywordsInvasive Pneumococcal Disease Pneumococcal Disease Pneumococcal Pneumonia Sequential Administration Pneumococcal Serotypes
- 2.European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe 2009 [online]. Available from URL: http://www.ecdc.europa.eu/en/Publications/0910_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf [Accessed 2011 Nov 17]
- 4.Centers for Disease Control and Prevention. 2011. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, provisional, 2010 [online]. Available from URL: http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf. [Accessed 2012 Mar 14]
- 8.Moberly SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008 Jan 23; (1): CD000422Google Scholar
- 16.Dagan R, Patterson S, Juergens C, et al. Efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) in preventing nasopharyngeal colonization with PCV7 serotypes: a randomized, double-blind trial [abstract]. 8th International Symposium on Pneumococci and Pneumococcal Diseases; 2012 Mar 11–15; Iguacu FallsGoogle Scholar
- 17.Pfizer. Prevenar® 13: US prescribing information [online]. Available from URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=501 [Accessed 2012 Apr 3]
- 18.European Medicines Agency. Prevenar 13: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf [Accessed 2012 Mar 3]
- 19.Pfizer. Pfizer receives FDA approval to extend use of Prevnar 13 for prevention of pneumococcal pneumonia and invasive disease in adults 50 years and older [online]. Available from URL: http://www.pfizer.com/news/ [Accessed 2012 Jan 24]
- 20.Jackson L, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [abstract no. O 425]. 21st European Congress of Clinical Microbiology and Infectious Diseases; 2011 May 7–10; MilanGoogle Scholar
- 22.Greenberg RN, Gurtmann A, Frenck R, et al. A phase 3, randomized, active-controlled trial to evaluate the safety, tolerability, and immunogenicity of sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) administered at 1-year intervals in PPSV23-naive adults 60–64 years of age [abstract no. 665 plus poster). 49th Annual Meeting of the Infectious Diseases Society of America; 2011 Oct 20–23; Boston (MA)Google Scholar
- 23.Jackson L, Gurtman A, van Cleef K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in pneumococcal vaccine naive adults, 50–64 years of age [abstract no. O 426]. 21st European Congress of Clinical Microbiology and Infectious Diseases; 2011 May 7–10; MilanGoogle Scholar
- 24.Merck and Co., Inc. Pneumovax® 23 (pneumococcal vaccine polyvalent): US precribing information [online]. Available from URL: http://merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf [Accessed 2012 Mar 19]
- 25.US Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines [online]. Available from URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf [Accessed 2012 Mar 19]
- 28.Study evaluating a 13-valent pneumococcal conjugate vaccine (13vPnC) in adults (CAPITA) [ClinicalTrials.gov identifier NCT00744263]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 23]